- Prioritizes cash preservation and controlled VINIA growth while concentrating CDMO resources on advanced programs with near-term manufacturing potential
All figures stated in this news release are in
Third Quarter and 2026 Financial Results Highlights
- Q3 2026 revenue was
$7.9 million , compared with$8.8 million in Q2 2026 and$9.1 million in Q3 2025. The decline reflected the Company's deliberate moderation of lower-return customer acquisition in the Products Business Unit, as part of its strategy to build a healthier, more profitable revenue base, as well as the timing of CDMO development revenue. Gross margin was 54%, compared with 58% in Q2 2026 and approximately 61% in Q3 2025, reflecting a revenue mix weighted toward Products, with a lower contribution from higher-margin CDMO development revenue. - Operating loss was
$3 million , compared with$2.5 million in Q2 2026 and$0.9 million in Q3 2025. The sequential increase reflected lower gross profit, partly offset by lower operating expenses quarter over quarter, while the year-over-year increase reflected higher gross profit in Q3 2025, as well as one-time, non-cash revaluation income recognized in that quarter, both of which resulted in a lower operating loss in Q3 2025 compared with Q3 2026. - Cash, cash equivalents and bank deposits totaled
$12.5 million atSeptember 30, 2026 , versus$16.2 million atJune 30, 2026 and$23 million atDecember 31, 2025 .
"Our third-quarter results reflect a period of deliberate transition," commented Dr.
"Toward the end of the second quarter, we began implementing changes to VINIA's marketing and sales strategy designed to drive profitability. These changes have resulted in a moderate decline in revenue, which we anticipated as part of our sales and marketing efficiency initiatives, and we expect the benefits of these improvements along with revenue growth to become evident beginning in the first quarter of 2027. On the CDMO development side, we are focusing our resources on the fragrance compound, multiple sweetener compounds with
"We believe focus—not the number of projects in development—will determine our speed of commercialization and ultimately our returns on invested capital."
Three execution priorities
- Cash preservation and conditional manufacturing investment.
- The Company intends to add manufacturing capacity gradually, in phases aligned with demonstrated demand, in order to preserve cash.
- Reduction of fixed operation costs, including consolidation of development sites in 2027.
- Controlled VINIA growth. Management intends to prioritize efficient customer acquisition, retention, margin discipline and cash contribution rather than pursuing top-line growth irrespective of economics.
- CDMO focus on select programs and faster progression. Resources will be concentrated on programs with the clearest commercial and manufacturing pathways.
2027 priorities include; completing development of three advanced projects - the rare, high-value, plant-based fragrance ingredient, the Saffron compound, and the natural sweetener molecules; and licensing our unique molecules' assets. The aim is to move advanced assets into production and commercialization with greater speed and lower resource dispersion.
Third Quarter and Recent Operational Highlights
- In August, the Company signed the CDMO division's first manufacturing and supply agreement, an exclusive agreement covering the scaled production of a rare, high-value, plant-based fragrance ingredient. The agreement extends an existing multi-stage development program with a
UAE -based customer.
The source plant is endangered due to overharvesting and habitat loss, and the ingredient is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of
Following the successful completion of Stage 1 development in
- In September, BioHarvest launched single-dose VINIA Daily Chews, designed to complement the existing VINIA portfolio, broaden consumer choice and provide an additional pathway for customer acquisition, retention, market expansion and revenue growth.
VINIA also demonstrates the commercial versatility of the Botanical Synthesis platform. Botanical Synthesis produces plant-based compositions in a versatile powder format, and VINIA gives prospective CDMO customers a commercial example of how a BioHarvest composition can progress from plant-cell development through scaled manufacturing and into differentiated consumer formats.
Third Quarter 2026 Financial Results Summary
Revenues for the third quarter of 2026 were
Cost of revenue was
Gross profit in the third quarter of 2026 was
R&D expenses totaled
Sales and marketing expenses totaled
G&A expenses totaled
Net loss for the third quarter of 2026 totaled
Adjusted EBITDA loss - a non-IFRS measure - totaled
Cash and cash equivalents, together with bank deposits, as of
Full-Year 2026 Guidance
In order to set the Company for success in 2027 and creating substantial shareholder value, the actions taken in the beginning of Q3 have resulted in changes to the 2026 financial results.
Full-year revenue guidance for the VINIA D2C business has been revised to
Largely driven by the 20-ton plant-based fragrance supply agreement (estimated to generate revenue of
On a consolidated basis, the Company now expects full-year 2026 revenue of
Third Quarter 2026 Earnings Call Information
Date:
Time:
Webcast: https://events.q4inc.com/attendee/792571252
The Q3 2026 Financial Results conference call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure participation.
A recording of the webcast will be available for replay on the Company's website within the Investor Relations/Events & Presentations section.
Use of Non-IFRS Financial Measures
This press release includes Adjusted EBITDA, a non-IFRS measure, including on a segment basis for the CDMO Services and Products business units. Adjusted EBITDA is not a standardized financial measure under IFRS and might not be comparable to similar financial measures disclosed by other issuers. It should not be considered as an alternative to operating loss or any other measure of financial performance under IFRS. Adjusted EBITDA represents operating profit (loss) before depreciation and amortization, adjusted for share-based payment. The Company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the Company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the Company's business as determined in accordance with IFRS. Investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to operating loss, its most directly comparable IFRS measure, is shown below.
IFRS OPERATING LOSS TO ADJUSTED EBITDA RECONCILIATION
| Unaudited | ||||||
| In USD thousands | ||||||
| For the three-month period ended | ||||||
| 2026 | 2025 | |||||
| CDMO Services | Products | Total | CDMO Services | Products | Total | |
| Operating (Loss) | (2,099) | (943) | (3,042) | (514) | (406) | (920) |
| Depreciation and Amortization | 527 | 76 | 603 | 311 | 74 | 385 |
| Share Based Payment | 158 | 240 | 398 | 50 | 83 | 133 |
| Adjusted EBITDA (Non-IFRS) | (1,414) | (627) | (2,041) | (153) | (249) | (402)(*) |
(*) The Adjusted EBITDA figures for the three months ended
About BioHarvest
BioHarvest (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products based on its botanical synthesis technology. To learn more, please visit?www.bioharvest.com.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-looking information" within the meaning of applicable Canadian securities laws (together, "forward-looking statements"), which can often be identified by words such as "expects," "anticipates," "intends," "plans," "estimates," "will," "may" and similar expressions. These include statements regarding the Company's 2026 guidance and 2027 priorities; the expected return to VINIA revenue growth; the timing of fragrance development, production and revenue; manufacturing capacity and cost reductions; CDMO development, licensing and new projects; and the Company's need for, and ability to obtain, additional capital.
These statements are based on management's current assumptions, including that the Company can acquire and retain VINIA customers at an acceptable cost; CDMO development revenue is recognized in the fourth quarter of 2026 as currently expected; gross margin and operating expenses remain consistent with current levels; the Company can complete Stage 2 fragrance development within the expected timeframe, begin limited production as early as the first quarter of 2027, scale up production and deliver the anticipated 20 tons of fragrance composition in 2027-2028 at the agreed pricing; its fragrance customer performs its obligations under the supply agreement; it can rely on its other customers and partners; it can operate without material disruption in Israel; and it can obtain financing on acceptable terms. These assumptions may prove incorrect.
Actual results may differ materially due to risks including: the Products strategy may not improve profitability or restore growth; the Company may need to further revise its 2026 guidance; fragrance revenue depends on successful development and delivery, and near-term CDMO prospects depend largely on one customer; manufacturing scale-up; reliance on partners; regulatory risks for nutraceutical products; currency fluctuations; and conditions in Israel and the Middle East. There is no assurance of new CDMO contracts, that development agreements will proceed or that compounds will be commercialized, and higher revenue may not result in profitability. See "Risks and Uncertainties" in the Company's MD&A for the three and nine months ended September 30, 2026 and its other filings on EDGAR (www.sec.gov) and SEDAR+ (www.sedarplus.ca).
The 2026 guidance and the estimated 2027-2028 revenue under the fragrance supply agreement are "financial outlook" under Canadian securities laws, provided to help readers understand management's current expectations, and may not be appropriate for other purposes. Forward-looking Adjusted EBITDA is not reconciled to operating loss because items such as share-based payment cannot be predicted without unreasonable efforts. Readers should not place undue reliance on forward-looking statements, which speak only as of the date of this news release. The Company undertakes no obligation to update them, except as required by applicable law.
BioHarvest Company Contact:
Justin Meiklem
Head of Corporate Communications
(604) 622-1186 | 778.686.3855
info@bioharvest.com
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Financial Position
USD dollars in thousands

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/323713_biohtable1.jpg
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss
USD in thousands, except per share data

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/323713_biotable2.jpg
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity
USD in thousands, except per share data

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/323713_biohtable3.jpg
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Cash Flows
USD in thousands

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/323713_biohtable4.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323713
SOURCE BioHarvest Sciences Inc.